-
Electronic (PDF)
-
Site License
-
Enterprisewide
Cangene Corporation - Product Pipeline Review - Q4 2010
Global Markets Direct, December 2010, Pages: 44
Cangene Corporation – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Cangene Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Cangene Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cangene Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cangene Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cangene Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Cangene Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cangene Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cangene Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cangene Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cangene Corporation and identify potential opportunities in those areas.
List of Tables
List of Figures
Cangene Corporation Snapshot
Cangene Corporation Overview
Key Information
Key Facts
Cangene Corporation – Research and Development Overview
Key Therapeutic Areas
Cangene Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Cangene Corporation – Pipeline Products Glance
Cangene Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cangene Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cangene Corporation – Drug Profiles
Anthrax Immune Globulin
Product Description
Mechanism of Action
R&D Progress
Botulism Antitoxin Heptavalent (Equine) Types A-G
Product Description
Mechanism of Action
R&D Progress
TST10088
Product Description
Mechanism of Action
R&D Progress
Ebola/Marburg Immune Globulins
Product Description
Mechanism of Action
R&D Progress
Immune Globulin Intravenous Program
Product Description
Mechanism of Action
R&D Progress
PEP 35
Product Description
Mechanism of Action
R&D Progress
Ricin immune globulin
Product Description
Mechanism of Action
R&D Progress
Cangene Corporation – Pipeline Analysis
Cangene Corporation – Pipeline Products by Therapeutic Class
Cangene Corporation – Pipeline Products by Route of Administration
Cangene Corporation – Pipeline Products by Molecule Type
Cangene Corporation – Company Statement
Cangene Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 14, 2010: Cangene Develops Immune Globulin Intravenous
Jun 14, 2010: Cangene Develops Immune Globulin Intravenous
Jun 14, 2010: Cangene Develops Immune Globulin Intravenous
Apr 23, 2010: Cangene Receives Canadian Approval For Hepatitis B Therapeutic For Second Indication
Apr 20, 2010: Cangene assumes U.S. commercialization rights for WinRho SDF
Apr 20, 2010: Cangene assumes U.S. commercialization rights for WinRho SDF
Mar 26, 2010: Health Canada Endorsed Important Safety Information Regarding WinRho SDF (Rho(D) Immune Globulin (Human))
Mar 26, 2010: Health Canada Endorsed Important Safety Information Regarding WinRho SDF (Rho(D) Immune Globulin (Human))
Mar 19, 2010: Cangene's Hepatitis B Product Approved By European Commission
Dec 18, 2009: Cangene Receives European Positive Opinion For Hepatitis B Product
Financial Deals Landscape
Cangene Corporation, Deals Volume Summary, 2004 to YTD 2010
Cangene Corporation, Deals Summary By Region, 2004 to YTD 2010
Cangene Corporation, Deals Summary, 2004 to YTD 2010
Cangene Corporation Detailed Deal Summary
Asset Purchase
Cangene Acquires US Commercial Rights Of HepaGam From Apotex
Acquisition
Cangene Acquires Twinstrand Therapeutics
Equity Offering
Cangene Completes Public Offering Of $31 Million
Upfront Chromatography Enters Into Co-Development Agreement With Cangene
Licensing Agreements
Upfront Chromatography Enters Into License Agreement With Cangene
Maxygen Terminates Option Licensing Agreement With Cangene
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
